Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting

AIDS

Volumn 25, Issue 9, 2011, Pages 1189-1197

  Hawkins, Claudia ^a,b   Chalamilla, Guerino ^b,c   Okuma, James ^c   Spiegelman, Donna ^c,d   Hertzmark, Ellen ^c   Aris, Eric ^b   Ewald, Tarcila ^b   Mugusi, Ferdinand ^e   Mtasiwa, Deo ^f   Fawzi, Wafaie ^b,c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MANAGEMENT AND DEVELOPMENT FOR HEALTH   (Tanzania)

^c Department of Nutrition ^*  (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^f MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

Author keywords

Africa; HIV treatment outcomes; sex

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROPATHY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; TANZANIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URBAN AREA;

EID: 85027922190     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283471deb     Document Type: Article

References (37)

1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
2. Garća de la Hera M, Ferreros I, del Amo J, Garća de Olalla P, Perez-Hovos S, Muga R, et al. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 2004; 58:944-950. (Pubitemid 39424704)
3. Finkel DG, John G, Holland B, Slim J, Smith SM. Women have a greater immunologic response to effective HIV-1 therapy. AIDS 2003; 17:2009-2011. (Pubitemid 37070297)
4. Collazos J, Asensi V, Cartón JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007; 21:835-843. (Pubitemid 46573155)
5. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008; 168:532-540.
6. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577. (Pubitemid 33096808)
7. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452-461. (Pubitemid 36363161)
8. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31:11-19.
9. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, Van der Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 2008; 47:441-448. (Pubitemid 351366961)
10. Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, et al., The Italian Antiretroviral Treatment Group. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005; 19:577-583. (Pubitemid 40543980)
11. Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre and highly active antiretroviral therapy eras. AIDS 2005; 19:357-370. (Pubitemid 40446182)
12. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007; 60:724-732. (Pubitemid 47439674)
13. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008; 13:513-519. (Pubitemid 351533602)
14. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenol B, Saghayam S, Yepthomi T, et al. Gender-based differences in treatment and outcome among HIV patients in South India. J Womens Health (Larchmt) 2008; 17:1471-1475.
15. Kipp W, Alibhai A, Saunders LD, Senthilselvan A, Kaler A, Konde-Lule J, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care 2010; 22:271-278.
16. Alibhai A, Kipp W, Saunders LD, Senthilselvan A, Kaler A, Houston S, et al. Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda. Int J Womens Health 2010; 2:45-52.
17. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776. (Pubitemid 44330743)
18. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10 000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873-882. (Pubitemid 351563837)
19. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008; 17:47-55. (Pubitemid 351197536)
20. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIVinfected South African adults. J Acquir Immune Defic Syndr 2006; 43:78-84. (Pubitemid 44306492)
21. The United Republic of Tanzania, Ministry of Health and Social Welfare. National Guidelines for the Management of HIV and AIDS, National AIDS Control Programme (NACP), Third Edition, 2008.
22. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO Press; 2006. pp. 1-128.
23. Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G. Longitudinal Data analysis. Generalized estimating equations for longitudinal data analysis. Boca Raton, FLA: CRC Press, Taylor and Francis Group. 2009. Chapter 3: 43-79.
24. Govindarajulu US, Malloy EJ, Ganguli B, Spiegelman D, Eisen EA. The comparison of alternative smoothing Methods for fitting nonlinear exposure-response relationships with Cox Models in a simulation study. Int J Biostat 2009; 5:2.
25. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997; 16:1515-1527. (Pubitemid 27322655)
26. DeSilva MB, Merry SP, Fischer PR. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 2009; 21:70-77.
27. Smith CA, Sabin CA, Youle MS, Lampe FC, Bhagani S, Madge S, et al. Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender. J Acquir Immune Defic Syndr 2007; 46:62-67. (Pubitemid 47507435)
28. Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, Spurrier J, Vermund SH. Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr 2008; 47:615-622. (Pubitemid 351442020)
29. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-2168. (Pubitemid 37338889)
30. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 2007; 4:106-119. (Pubitemid 47248489)
31. Baylor MS, Johann-Liang R. Hepatotoxicty associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35:538-539.
32. Waldron I. Recent trends in sex mortality ratios for adults in developed countries. Soc Sci Med 1993; 36:451-462.
33. Muyer MT, Buntinx F, Mapatano MA, De Clerch M, Truyers C, Muls E. Mortality of young patients with diabetes in Kinshasa, DR Congo. Diabet Med 2010; 27:405-411.
34. Peer N, Steyn K, Dennison CR, Leyitt NS, Nyo MT, Nel JH, et al. Determinants of target organ damage in black hypertensive patients attending primary healthcare services in Cape Town: the Hi-Hi study. J Hypertens 2008; 21:896-902.
35. Reynolds SJ, Nakigozi G, Newell K. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
36. DART Virology Group DART and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
37. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007; 21:2293-2301. (Pubitemid 350287455)